Zura Bio Ltd

Zura Bio Ltd, a clinical-stage biopharmaceutical company focused on immunology and inflammation, filed a Form 10-Q with the SEC on August 12, 2022, under CIK 0001855644, covering its quarterly operations as a newly public entity in the life sciences sector. The filing reflects the company's early-stage reporting obligations following its emergence onto public markets, placing it within the broader cohort of biotechnology-focused vehicles tracked across the SPAC ecosystem. Zura Bio operates in the drug discovery and development space, targeting conditions driven by immune dysregulation. For full filing data, deal history, and ongoing status updates on Zura Bio Ltd and hundreds of other SPAC-linked entities, sign up for SpacDesk at spacdesk.com.